Results 151 to 160 of about 202,497 (309)

Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1‐Linked Amyotrophic Lateral Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Tofersen is the first effective and approved therapy for superoxide dismutase 1 (SOD1)‐associated amyotrophic lateral sclerosis (ALS [SOD1‐ALS]). Following treatment with tofersen, neurofilament levels in patients' cerebrospinal fluid (CSF) and serum seem to respond earlier than clinical parameters.
Christina Steffke   +36 more
wiley   +1 more source

MOTOR DRIVER'S PALSY. [PDF]

open access: green, 1907
DonaldF. Shearer
openalex   +1 more source

Intranasal Wharton's Jelly‐Derived Mesenchymal Stem Cell Therapy, Alone or in Conjunction With Therapeutic Hypothermia, Alleviates Neonatal Hypoxic‐Ischemic Brain Injury in Mice

open access: yesAnnals of Neurology, EarlyView.
This study demonstrates that intranasal Wharton's jelly‐derived mesenchymal stem cell (WJ‐MSC) administration at 3 or 10 days post‐insult reduced the lesion size and sensorimotor impairment following neonatal hypoxic‐ischemic (HI) brain injury in mice. WJ‐MSCs expressed receptors for HI‐upregulated chemokines and migrated from the nasal cavity into the
Caroline G. M. de Theije   +9 more
wiley   +1 more source

BULBAR PALSY IN MULTIPLE SCLEROSIS [PDF]

open access: green, 1907
Thos. J. Orbison
openalex   +1 more source

Happy 75th National Institute of Neurological Disorders and Stroke

open access: yesAnnals of Neurology, EarlyView.
For 75 years the National Institute of Neurological Disorders and Stroke has led neurological research in the US. Many thousands of people have volunteered in research and thousands of investigators devoted their careers to pursuing better treatments of neurological disorders.
Walter J. Koroshetz
wiley   +1 more source

Home - About - Disclaimer - Privacy